Previous 10 | Next 10 |
home / stock / polbf / polbf news
(NewsDirect) Proactive research analyst Robin Davison speaks to Thomas Warner after publishing a new report on Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF), following the release of selected data from its human volunteer LPS challenge trial for lead molecule POLB 001. Contact Details ...
(NewsDirect) Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive's Thomas Warner after announcing the data readout from an LPS human challenge trial for POLB 001, the infectious disease focused biopharma company's lead molecule. Skillington says that ...
(NewsDirect) Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) VP of Business Development David English speaks to Proactive's Thomas Warner about the work he's doing to progress the clinical stage infectious disease pharmaceutical company's lead asset POLB 001. English says that Poolbeg is "...
(NewsDirect) Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive's Thomas Warner after announcing that the company has submitted a patent application for the use of POLB 001 in a new oncological indication. Skillington explains the reasons for the strategic e...
Complements strong initial data from LPS challenge trial and is in line with stated objective at IPO to expand POLB 001 to additional indications Key Highlights · Newly filed patent application to protect use of POLB 001 for new oncology indicationScientific findings indicate POLB ...
(NewsDirect) Poolbeg Pharma PLC (OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive after announcing initial data analysis, including a 'clear dose-related response', for its drug, POLB 001, a potential treatment for severe influenza. Skillington says the 'early data readout' indicates t...
Early data read out indicates a successful LPS human challenge trial Key Highlights POLB 001 demonstrated a marked reduction in both systemic and localised inflammatory response compared to volunteers who received placebo A clear dose-response relationship was demonstrated We...
Poolbeg identifies new potential drug candidates for Respiratory Syncytial Virus infections as part of Artificial Intelligence Programme Collaboration with OneThree Biotech identifies novel RSV treatments First time RSV drug candidates identified using AI Candidates with existing Pha...
Poolbeg exclusively licences innovative oral delivery technology for metabolic syndrome related diseases Clinical trial to demonstrate technology can safely deliver GLP-1 to commence in H1 2023 Prof Brendan Buckley joins Poolbeg's Scientific Advisory Board to guide clinical development o...
POLB 001 LPS human challenge clinical trial successfully completed No serious adverse events reported Results of full data analysis expected in Q2 2023 LONDON, UK / ACCESSWIRE / December 12, 2022 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) 'Poolbeg' or the 'Company'), a leading infe...
News, Short Squeeze, Breakout and More Instantly...
Poolbeg Pharma plc Ord GBP 0.0002 Company Name:
POLBF Stock Symbol:
OTCMKTS Market:
Poolbeg Pharma plc Ord GBP 0.0002 Website:
LONDON, UNITED KINGDOM / ACCESSWIRE / July 10, 2024 / TR-1: Standard form for notification of major holdings This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the U...
Change of Registered Address LONDON, UK / ACCESSWIRE / July 2, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), ('Poolbeg' or the 'Company'), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medi...
Results of Annual General Meeting LONDON, UNITED KINGDOM / ACCESSWIRE / June 17, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) ‘Poolbeg' or the ‘Company'), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines ta...